Skip to main content
. Author manuscript; available in PMC: 2017 Apr 17.
Published in final edited form as: Leukemia. 2016 Oct 17;31(3):688–696. doi: 10.1038/leu.2016.284

Figure 1. DOCK2 is expressed in hematopoietic cell lines and leukemic blasts from patient samples, and interacts with FLT3, FLT3/D835 and FLT3/ITD.

Figure 1

(A) Expression of DOCK2 in established hematopoietic cell lines that lack FLT3 (K562) or express wild-type FLT3 (SEM K2), FLT3/D835 (Ba/F3:FLT3/D835Y) or FLT3/ITD (MV4;11 and Molm 14) by Western blotting. DOCK2 is absent in the HS5 bone marrow stroma cell line. (B) Expression of DOCK2 in patient samples of AML from the peripheral blood (PB) and bone marrow (BM) that express either wild-type FLT3 (WT) or FLT3/ITD (ITD). (C) Co-immunoprecipitation of FLT3, FLT3/D835 and FLT3/ITD with DOCK2 in cell lines and (D) AML patient samples.